08:05 AM EDT, 08/05/2022 (MT Newswires) -- Immunovant (IMVT) reported a fiscal Q1 net loss Friday of $0.35 per diluted share, widening from a $0.31 loss a year earlier.
Analysts polled by Capital IQ expected a loss of $0.40 per share.
As expected, no revenue for the quarter ended June 30 was reported.
At the end of June, the company had a cash balance of $427 million, which it expects to provide cash runway into 2025.
Shares of the clinical stage biopharma firm were up more than 3% in recent pre-market trading.
Price: 4.52, Change: +0.14, Percent Change: +3.2